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OBJECTIVES: To carry-out a cost-effectiveness analysis (CEA) of the effect of Prega-
balin (PGB) versus usual care in refractory out-patients with Generalized Anxiety 
Disorder (GAD) treated according with usual medical practice in Mental Health 
Centers in Spain. METHODS: CEA was carried-out by means of a nested case-control 
design which used secondary data extracted at random from a 6-month cohort pro-
spective observational study (the ADAN study) conducted to ascertain cost-of-illness 
in GAD (DSM-IV criteria). Refractory subjects were those who claimed of persistent 
symptoms of anxiety and showed suboptimal response (HAM-Anxiety scale q 16) 
after a course of standard doses of any anti-anxiety drug, alone or in combination, 
for 6 months. At baseline, patients could switch to PGB (monotherapy or add-on) or 
to usual care, alone or in combination, which were considered cases and controls 
respectively. Health outcomes included quality-adjusted life years (QALYs) gain by 
EQ-5D. A 3rd-payer perspective was chosen for the CEA analysis in year 2009. Sensi-
tivity analysis was performed by bootstrapping techniques (10000 re-samples were 
obtained) in order to obtain a cost-effectiveness acceptability curve. RESULTS: A total 
of 858 refractory subjects (mean baseline HAM-A; score 25.7) were identiﬁed; 429 in 
each of the PGB and UC group. Compared with UC, PGB was associated with signiﬁ-
cant higher QALY gain after 6 months of treatment; 0.12250.0995 vs 0.10090.0938 
(p  0.001), but signiﬁcantly increased health care costs; a1,240.61,407.4 vs 
a931.4940.2 (p  0.0001). The deterministic ICER ratio was a14,287 per QALY 
gained with a re-sampling ICER of a15,804 (95 CI: 15,064–16,545). The 90% of 
re-samples fold below a25,052 threshold and 95% a a30,000. CONCLUSIONS: 
Despite the design of the primary study, this evaluation could suggest that pregabalin 
may be cost-effective in comparison with usual care in refractory out-patients with 
Generalized Anxiety Disorders managed in Mental Health Centers under usual 
medical practice in Spain.
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OBJECTIVES: Aggressive behavior in early childhood affects daily life of both, the 
children and their surroundings, resulting in serious economic implications to society. 
This study analyses the cost-effectiveness of the Incredible Years (IY) parent program, 
a manualized behavioural parent training aiming at the improvement of parenting          
skills in order to reduce child aggressive behaviour -, compared to care as usual (CAU) 
in preschoolers at risk of a chronic pattern of conduct problems. METHODS: Data 
was collected on intervention costs and for both groups at different moments in time 
(before intervention, after intervention, one- and two-year follow-up) on effects 
(observed Negative Child Behavior) and on costs due to the use of public services, 
child’s damage, travel costs and productivity losses. A cost-effectiveness study was 
conducted using different perspectives that were public authorities, parent and society. 
RESULTS: Children from the IY parent program, in comparison to CAU, had a sig-
niﬁcant larger decrease on Negative Child Behavior. An effect that was even larger if 
taking only children with severe aggressive behavior. The monetary beneﬁts per child 
were larger than the intervention costs, taking the society’s perspective and the parent’s 
perspective respectively. However, from the public authorities’ perspective, the net  
costs per child to reduce the Negative Child Behavior score by one were a106. Basic  
program (12 sessions in place of 18), social worker as trainer (psychologist in base-
line), not considering informal help resulted in better a CER compared to baseline, 
whereas costs for recruiting, parking fees and the inclusion of loss of leisure time 
would. CONCLUSIONS: Seen from the society’s perspective, the intervention is 
unambiguously dominant over CAU. Children from the IY parent program had 
a signiﬁcant larger decrease on Negative Child Behavior than those from the CAU 
condition. And from the society’s perspective the IY parent program was even 
cost-saving.
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IN SCHIZOPHRENIA
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OBJECTIVES: To assess the cost effectiveness of risperidone LAI compared with oral 
risperidone and oral olanzapine over a 1-year time period in outpatient with schizo-
phrenia who had previously suffered a relapse requiring hospitalization as south Korea 
health care system. METHODS: Published medical literature and hospital electronic 
data were used to populate a decision-analysis model comparing the three treatment 
alternatives. The model captures: rates, frequency, duration of hospitalization, stable 
days(duration of out-patient follow-up) that health care resource utilization and 
associated costs. Primary outcomes were: the proportion of patient re-hospitalization; 
the frequency of hospitalization per patient; the number of hospitalization days per 
patient; the number of stable days and total direct and indirect cost per patient per 
years. Costs are in year 2007 Korea Wons. RESULTS: Based on model projections, 
the proportions of patients experiencing re-hospitalization after 1 year treatment were 
19.0% for risperidone LAI, 25.0% oral olanzapine and 26.6% for oral risperidone, 
respectively. The mean number of days of re-hospitalization per patient per year was 
16.6 for risperidone LAI, 21.9 oral olanzapine and 23.1 for oral risperidone, respec-
tively. This would translate into total cost savings with risperidone LAI compared 
with oral olanzapine of 46,011, while oral risperidone more spend 78,905 respectively. 
The result of sensitivity analyses, patients re-hospitalization rate during 6-month 
treatment were total cost savings with risperidone LAI compared with oral risperidone 
and oral olanzapine. When drug cost of risperidone LAI, reducing 30% and 75%, 
compared with oral risperidone and oral olanzapine are cost-effective medicine. CON-
CLUSIONS: The use of risperidone LAI for treatment of outpatient with schizophrenia 
is predicted in this model to result in better clinical outcomes but higher total health 
care costs over 1 year than its comparators, oral risperidone and oral olanzapine. 
Risperidone LAI may therefore be carefully therapeutic option for outpatients with 
schizophrenia in the republic of Korea health care setting.
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OBJECTIVES: To assess the cost-effectiveness of olanzapine long-acting injection 
(OLAI) compared with risperidone long-acting injection (RLAI) for patients with 
schizophrenia in Norway. METHODS: A discrete event simulation (DES) model was 
developed from a Norwegian health care system perspective to estimate the costs and 
outcomes associated with OLAI vs. RLAI for patients with schizophrenia over a ﬁve 
year period. The model focuses on patients that have been non-adherent to oral medi-
cation resulting in recurrent relapses. These patients responded to oral treatment during 
the stablisation phase of their illness and have been modeled as entering the mainte-
nance phase of treatment. DES was considered an appropriate approach due to the 
heterogeneous nature of schizophrenia. Norwegian unit cost and resource utilisation 
data were used. Key clinical inputs were relapse rates and treatment discontinuation 
rates obtained from open-label studies. Occurrences of side-effects, such as post- 
injection syndrome, were accounted for. Cost and outcomes included direct medical 
costs and quality-adjusted life years (QALYs) discounted at a rate of 4%. A range of 
deterministic and probabilistic sensitivity analyses were conducted. RESULTS: Results 
were analysed over a 5-year time horizon. OLAI was found to be dominant over RLAI. 
Incremental costs and outcomes were 63,323 NOK (a7,085) and 0.07 QALYs. 
OLAI was associated with fewer relapses (1.41 vs. 1.81 for RLAI) and a longer time 
on treatment (3.98 years vs. 3.69 years for RLAI). Base case results were most sensitive 
to changes in the relapse and treatment discontinuation rates, the cost of relapse, and 
the time horizon. Probabilistic results conﬁrmed OLAI’s dominance over RLAI. CON-
CLUSIONS: The economic evaluation indicates that OLAI is highly cost-effective 
compared to RLAI. As an efﬁcacious and well-tolerated treatment, OLAI constitutes 
an important maintenance treatment option for patients with schizophrenia experienc-
ing recurrent relapse and previously struggling with adherence to oral medication.
PMH43
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OBJECTIVES: Compliance with pharmacologic treatment in schizophrenia is directly 
associated with the successful control of the condition. The objective of this study is 
to estimate the cost-effectiveness of quetiapine XR in the treatment of schizophrenia 
compared to paliperidone (ER) and quetiapine IR. METHODS: Model: A Markov 
model, with three disease states (mild, moderate and severe) was constructed with a 
time horizon of 1-year, based on Edwards 2005. The analysis was performed from 
the Turkish health care payer perspective. Patient group: Adult patients with schizo-
phrenia receiving treatment. Data sources: Clinical data were acquired from local and 
international literature. Resource use data were provided by an expert panel. Prices 
of medications and other costs related to treatment of schizophrenia were obtained 
from the Ministry of Health Drug Price List in November 2008, and the Price Lists 
of Social Security Institution in 2008, respectively. Outcomes: Clinical outcome 
was deﬁned as the number of relapses and hospitalizations within one year period. 
Economic outcome was the calculated annual cost of disease. Only direct medical 
costs, i.e. treatment, laboratory examinations and health care, were considered. 
RESULTS: Total annual cost of disease is a1.450 for quetiapine XR, lower as com-
pared to quetiapine IR (a1.653), quetiapine IR pool (a1,606) and paliperidone 
(a1.898). Annual hospitalizations rate is 1149 for quetiapine XR and paliperidone, 
and 1174 for quetiapine IR. Annual relapse rate is 2569 for quetiapine XR and pali-
peridone, and 2623 for quetiapine IR. Quetiapine XR, with its lower cost, is superior 
to paliperidone on cost-minimization manner. Quetiapine XR has dominated quetiap-
ine IR on cost-effectiveness manner. Sensitivity analyses prove that results are quite 
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robust. CONCLUSIONS: In the treatment of schizophrenia, quetiapine XR dominates 
quetiapine IR due to lower cost, reduced relapse and hospitalization rate and domi-
nates paliperidone due to lower cost. REFERENCE: Edwards NC et al. Pharmaco-
economics 2005;23(Suppl. 1):75–89.
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OBJECTIVES: To analyse effectiveness of ﬂupentixol compared to other ﬁrst and 
second generation antipsychotics for the treatment of schizophrenia in routine care. 
METHODS: A retrospective cohort study was conducted using administrative data 
from four sickness funds with a combined number of 12.6 million insured. Patients 
discharged from hospital with an ICD-10 diagnosis of schizophrenia in 2003 were 
followed for 12 months. Rehospitalisation during follow-up was analysed using a 
hurdle regression model. Differences in treatment costs, deﬁned as cost of pharmaceu-
tical and cost of inpatient care, were analysed assuming a gamma distribution for 
treatment costs and using a log-link-function. To control for possible confounding, 
the models adjusted for age, gender, and prior hospitalisations due to schizophrenia 
in 2000, 2001 and 2002. RESULTS: A total of 8610 insured were included, of which 
177 treated with ﬂupentixol during follow-up, while 429 and 2284 were treated with 
other ﬁrst and second generation antipsychotics, respectively. Compared to patients 
treated with ﬂupentixol (predicted hospitalisation for the average patient: 19 days), 
predicted hospitalisation did not differ signiﬁcantly for patients treated with other ﬁrst 
(16.9 days, p  0.0919) or second generation antipsychotics (19.5 days, p  0.1418). 
Predicted treatment costs for the average patient (age  41.5 years, male, prior hospi-
talisation 26.7 days per year) were a4384 if treated with ﬂupentixol, a7021 if treated 
with an other ﬁrst generation antipsychotic, and a6819 if treated with a second genera-
tion antipsychotic. Differences in treatment costs between ﬁrst and second generation 
antipsychotics increased with severity. CONCLUSIONS: The effectiveness of ﬂupen-
tixol preventing relapse in patients with schizophrenia appears to be similar to that 
of other ﬁrst and second generation antipsychotics. However, the low treatment costs 
for patients treated with ﬂupentixol might be explained by the small number of 
patients who were hospitalised (70 insured) and the larger share of patients treated 
with its depot formulation.
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THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN 
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POPULATION DATA
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OBJECTIVES: A cost-utility analysis of a new antidepressant agomelatine (Valdoxan) 
compared to generic venlafaxine and placebo in the treatment of MDD was performed 
from the Finnish societal perspective. METHODS: The analysis is based on a Markov 
state transition model with second-order Monte Carlo simulation and two year time-
frame. Conservatively, agomelatine and venlafaxine were assumed to be equally effec-
tive in the treatment of depressive symptoms, but to differ in costs, side effect proﬁles, 
clinically signiﬁcant sleep disorders during treatment, discontinuation rates and dis-
continuation symptoms based on agomelatine clinical trials. Finnish EQ-5D utilities, 
health care resource use, travelling and production losses (derived from the actual 
work rates of MDD patients using human capital approach) were estimated based on 
a Finnish study including 298 patients with MDD, adjusted for confounders (age, 
gender, marital status, income and education), and matched to model states and 
adverse events using two-stage multivariate models. The costs were presented in 2008 
value. Annual discounting rate considered was 3%. RESULTS: Compared to generic 
venlafaxine and placebo the treatment with agomelatine resulted in 0.012 and 0.066 
additional quality-adjusted life-years (QALY) gained, and in 356 and a126 additional 
treatment costs during the two year time-frame, respectively. The corresponding 
additional costs including production losses were 220 and a3255. Agomelatine was 
associated with an incremental treatment cost of a29,000/QALY gained compared to 
generic venlafaxine. When production losses were included, this ratio fell to a18,000/
QALY gained. According to cost-effectiveness acceptability frontier (excl. production 
losses), the probability of agomelatine’s cost-effectiveness was 57 and 90% with the 
willingness-to-pay levels of a30,000 and a50,000 per QALY gained, respectively. 
Agomelatine dominated placebo. One-way sensitivity analyses showed that the results 
were robust to key parameter changes. CONCLUSIONS: Agomelatine is a cost-
 effective treatment for MDD versus generic venlafaxine and dominant versus placebo 
based on the representative Finnish data.
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OBJECTIVES: Little or no information exist on the cost of mental health services in 
Africa, even though mental health disorders represent a major public health concern 
in the region, in terms of health and economic impact. The study estimated the total 
and average/unit costs of psychiatric hospital services (including inpatients and out-
patients services) to guide policy and psychiatric hospital management efﬁciency in 
Nigeria. METHODS: The study was exploratory and analytical, examining 2008 data. 
Using standardized costing methodology based on ingredient approach, top-down 
methodology was combined with step-down approach to allocate resources (overhead 
and indirect costs) to the ﬁnal cost centers. All costs associated with treatment of the 
psychiatric patients (including annualised costs of capital items) were measured on 
aggregate basis as well as on per capita basis. Costs were calculated from the perspec-
tive of the health care facility, and converted to US Dollars at the 2008 exchange rate. 
RESULTS: Personnel costs average over 75% in all departments. Unit cost of outpa-
tient visit is similar to the cost of inpatient day averaging $50, while cost per inpatient 
admission is about $3288. Cost of emergency consultation is about two times the cost 
of an outpatient visit or inpatient day. About 65 new outpatients could be treated 
for the cost of one inpatient admission. Levels of subsidization for inpatients are 
over 90% while ancillary services are not subsidized hence full cost recovery. Cost of 
drugs is about 4.4% of the total costs and each prescription averaged $7.48. 
CONCLUSIONS: The unit cost estimates fall within the European estimates for 
 psychiatric health services and WHO-CHOICE’s ‘high estimates’ for tertiary health 
facilities in SSA. Adequate research is needed to determine the cost of providing 
 psychiatric hospital services in Africa to inform effective policy and improved man-
agement efﬁciency for mental health services in the region.
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CLINICAL AND ECONOMIC OUTCOMES IN SCHIZOPHRENIA AND 
BIPOLAR DISORDER
Sanders KN1, Mychaskiw MA1, Alvir J1, Montejano LB2, Lenhart G3, O’Gorman C1
1Pﬁzer, New York, NY, USA, 2Thomson Medstat, Washington, DC, USA, 3Thomson 
Reuters, Cambridge, MA, USA
OBJECTIVES: Clinical efﬁcacy and symptom control are the primary basis for atypical 
antipsychotic (AAP) selection. Clinical effectiveness outcomes are less well studied as 
treatment considerations. Retrospective administrative-claims data analyses for patients 
with schizophrenia and bipolar disorder were completed to characterize the association 
between AP treatment and clinical and economic patient outcomes. METHODS: 
Patients with schizophrenia (n  2737) or bipolar disorder (n  9707) on AAP (aripip-
razole, olanzapine, risperidone, quetiapine or ziprasidone) treatment were identiﬁed in 
the 2004–2005 PharMetrics Patient-Centric Database. Patients with q12 months con-
tinuous enrollment before and after their earliest AAP claim were included in the analy-
ses and stratiﬁed by their most-recent AAP claim. Treatment cohorts were propensity 
score matched. Index treatment differences were characterized by multivariable regres-
sion models. Time to discontinuation (Cox proportional hazard regression), psychiatric 
admission probability (logistic regression) and expenditures (GLM) were evaluated. 
Post–index period costs were tallied. RESULTS: Schizophrenia patient cohorts 
were aripiprazole (n  367), olanzapine (n  755), risperidone (n  1004), quetiapine 
(n  404) and ziprasidone (n  207). Mean age range was 40–44 years. After propensity 
score matching, there were no signiﬁcant differences across cohorts in time to discon-
tinuation and psychiatric hospitalization probability. Total quetiapine expenditures 
were greater than ziprasidone ($16,417 vs. $12,547; p  0.0024). CONCLUSIONS: 
Limited statistical differences were observed in this population. Further research should 
be conducted to understand whether such differences occur in other large databases 
and their clinical and economic relevance for AAP patient populations.
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PAROXETINE AND LITHIUM IN ACUTE BIPOLAR DEPRESSION
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OBJECTIVES: To evaluate the cost-effectiveness of quetiapine extended release 
300 mg once daily (o.d.) in adult patients with acute bipolar depression compared 
with average standard adult doses of paroxetine 20 mg o.d. and lithium 1.2 g o.d. 
METHODS: A weekly cycle 7-state markov model was designed to evaluate the cost-
effectiveness of quetiapine extended release over a 3-year time horizon from the per-
spective of the UK National Health Service. Remission, treatment-emergent mania, 
discontinuations, signiﬁcant weight-gain (q7%) and extrapyramidal adverse event rate 
probabilities were used in the model. These, in the form of relative risks, were obtained 
from two separate indirect comparisons of quetiapine extended release versus parox-
etine and lithium with placebo as the common comparator. These comparisons were 
obtained from randomised blinded studies in the AstraZeneca trial registry for que-
tiapine in the treatment of acute bipolar depression. A systematic literature review was 
completed to identify suitable health state utility values. Costs included pharmacologi-
cal therapy and resource use associated with the treatment of mood events. Results 
were reported in cost (2009 values) per quality-adjusted life years (QALYs). A proba-
bilistic sensitivity analysis (PSA) was conducted to assess the robustness of the results. 
RESULTS: Quetiapine extended release was a cost-effective treatment option for 
adults with acute bipolar depression versus both paroxetine and lithium. The deter-
ministic incremental cost-effectiveness ratios were £1,541/QALY and £14,548/QALY, 
when quetiapine extended release was compared with paroxetine and lithium, respec-
tively. These results were supported in the probabilistic sensitivity analysis. Eighty-four 
percent and 92% of simulations found quetiapine extended release to be cost-effective 
at a threshold of £30,000/QALY versus paroxetine and lithium, respectively. 
 CONCLUSIONS: The results of this cost-utility analysis suggest that not only is 
